Avacta shares fly on impressive results from Covid-19 lateral flow test
Shares in diagnostics and innovative cancer therapies company Avacta (AVCT:AIM) jumped 10% to 257.6p on Tuesday after receiving clinical validation of its Covid-19 lateral flow test.Today's announcement follows up quickly on the...
20 April 2021